Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Company Drug

HutchMed’s Orpathys-Tagrisso Combo Shows Promise in NSCLC at WCLC

Fineline Cube Jul 13, 2022

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the publication of an abstract detailing the SAVANNAH...

Company Drug

Junshi Biosciences’ JS203 Bispecific Antibody Receives NMPA Green Light for NHL Study

Fineline Cube Jul 13, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...

Drug

Eli Lilly’s Trulicity + Insulin Combo Meets Goals in China’s AWARD-CHN3 Study

Fineline Cube Jul 13, 2022

Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...

Policy / Regulatory

China’s 7th VBP Round Yields 65.5% Drug Price Cuts, Foreign Firms Secure Bids

Fineline Cube Jul 13, 2022

China’s 7th national volume-based procurement (VBP) round concluded with winning bids averaging a 65.5% price...

Company Drug

CDE Grants Priority Review to Ascentage’s Olerembatinib and Roche’s Crovalimab

Fineline Cube Jul 12, 2022

The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...

Company Deals

Athenex Sells China Subsidiaries to TiHe Capital for USD 19 Million

Fineline Cube Jul 12, 2022

US-based Athenex Inc. (Nasdaq: ATNX) announced an agreement to sell all equity interests in its...

Company Deals

Tasly Pharmaceuticals and Mauna Kea Form JV to Commercialize Cellvizio in China

Fineline Cube Jul 12, 2022

China-based Tasly Pharmaceuticals (SHA: 600535) announced a joint venture (JV) with France’s Mauna Kea Technologies...

Company Medical Device

MicroPort MedBot’s Honghu Robot Wins FDA 510(k) Certification for Joint Replacement

Fineline Cube Jul 12, 2022

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that its in-house developed orthopedic surgery...

Company Medical Device

Venus Medtech’s Transcatheter Prosthetic Pulmonary Valve Approved by NMPA

Fineline Cube Jul 12, 2022

The National Medical Products Administration (NMPA) has approved Venus Medtech (Hangzhou) Inc’s (HKG: 2500) transcatheter...

Company Drug

Hengrui Medicine’s SHR-1701 + Ameile Combo Greenlit for EGFR-Mutated NSCLC Trial

Fineline Cube Jul 12, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that the National Medical Products Administration...

Company Drug

Eucure Biopharma Doses First Patient in YH003 + Keytruda Trial for Mucosal Melanoma

Fineline Cube Jul 12, 2022

Eucure Biopharma, a subsidiary of Sino-US contract research organization Biocytogen, announced that the first patient...

Company Drug

Overland ADCT BioPharma Launches Global Phase III Trial for Zynlonta in DLBCL

Fineline Cube Jul 12, 2022

Overland ADCT BioPharma, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC Therapeutics SA...

Company Drug

Bio-Thera Solutions Doses First Patient in BAT8006 Phase I Study for Solid Tumors

Fineline Cube Jul 12, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that the first patient has been dosed in a...

Company Deals

Neurophth and Abogen Partner on mRNA Therapy for Retinal Diseases

Fineline Cube Jul 11, 2022

China-based Neurophth Biotechnology Ltd, a gene therapy specialist, has partnered with compatriot mRNA drug developer...

R&D

Hong Kong Researchers Explore TES for Depression and Alzheimer’s Treatment

Fineline Cube Jul 11, 2022

Researchers at The University of Hong Kong’s Li Ka Shing Faculty of Medicine (HKUMed) and...

Company

CASI Pharmaceuticals Invests in Precision Immune Therapeutics for CID-103 Development

Fineline Cube Jul 11, 2022

US-based CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced the completion of a financing round for China’s...

Company

Sinopharm in Talks to Acquire BBI Life Sciences in USD 1B+ Deal

Fineline Cube Jul 11, 2022

China National Pharmaceutical Group Co., Ltd (Sinopharm) is reportedly considering a bid to acquire Shanghai-based...

Company Legal / IP

Acer Therapeutics and Relief Therapeutics Awarded China Patent for ACER-001

Fineline Cube Jul 11, 2022

US-based Acer Therapeutics Inc. (Nasdaq: ACER) and Swiss partner Relief Therapeutics Holding SA (SWX: RLF)...

Company Deals

Bangbang Robot Raises USD 14.9M in Series B to Expand Mobility Tech

Fineline Cube Jul 11, 2022

Shanghai-based Bangbang Robot Co., Ltd, a developer of assisted mobility technology, has raised nearly RMB...

Company Drug

OBI Pharma Halts OBI 888 Trial Over Manufacturing Costs, Shifts Focus to Globo H ADC

Fineline Cube Jul 11, 2022

Taiwan-based OBI Pharma (TPEx: 4174) announced the discontinuation of a Phase I/II trial for its...

Posts pagination

1 … 692 693 694 … 707

Recent updates

  • Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
  • NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
  • Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
  • Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
  • Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Company Medical Device

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.